| 1.28 -0.03 (-2.29%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.58 | 1-year : | 1.69 |
| Resists | First : | 1.35 | Second : | 1.45 |
| Pivot price | 1.33  |
|||
| Supports | First : | 1.21 | Second : | 1 |
| MAs | MA(5) : | 1.28  |
MA(20) : | 1.34 |
| MA(100) : | 1.77 |
MA(250) : | 1.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.7 |
D(3) : | 30.1 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 2.98 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDXS ] has closed above bottom band by 27.4%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.32 - 1.33 | 1.33 - 1.33 |
| Low: | 1.25 - 1.26 | 1.26 - 1.26 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Thu, 22 Oct 2026
Temporary Delays in siRNA Manufacturing Mask Codexis’ (CDXS) High-Option Value - Yahoo Finance
Tue, 13 Oct 2026
An $8.62K share sale proposed by Codexis (CDXS) officer Georgia Erbez involves a vested stock grant. - Stock Titan
Tue, 13 Oct 2026
Officer Alison Moore proposes selling 6,335 Codexis (Nasdaq: CDXS) shares. - Stock Titan
Tue, 11 Aug 2026
Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside - TradingView
Tue, 11 Aug 2026
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Tue, 11 Aug 2026
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 110 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 70.1 (%) |
| Shares Short | 4,840 (K) |
| Shares Short P.Month | 3,850 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | -39.6 % |
| Operating Margin | -75.3 % |
| Return on Assets (ttm) | -11.8 % |
| Return on Equity (ttm) | -69.4 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.7 |
| EBITDA (p.s.) | -0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -3.88 |
| PEG Ratio | 13.5 |
| Price to Book value | 3.55 |
| Price to Sales | 1.8 |
| Price to Cash Flow | -13.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|